Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Combination Therapies and Personalized Medicine

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...

Myasthenia Gravis: Overview and Treatment

Myasthenia Gravis: Overview and Treatment

Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which leads...

Alzheimer's Disease: Treatment

Alzheimer's Disease: Treatment

Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...

Drug Therapy

Drug Therapy

The advent of drug therapy has profoundly shaped modern mental health care, providing targeted treatments for a range of psychological disorders. Psychotherapeutic drugs, classified into antianxiety, antidepressant, and antipsychotic medications, address symptoms across anxiety disorders, mood disorders, and schizophrenia. While these medications have transformed patient outcomes, they require careful management due to their potential side effects and limitations.
Antianxiety Medications

Microorganisms in Medicine and Therapeutics

Microorganisms in Medicine and Therapeutics

Microorganisms play a fundamental role in vaccine development, gene therapy, and therapeutic production. Their biological properties are harnessed to advance medicine and public health. Beyond immunization, microorganisms contribute to gut health, antibiotic synthesis, and genetic disease treatment.Live Attenuated and Inactivated VaccinesLive attenuated vaccines, such as the measles, mumps, and rubella (MMR) vaccine, utilize weakened forms of pathogens to closely resemble natural infections.

Multiple Sclerosis l: Introduction

Multiple Sclerosis l: Introduction

Multiple sclerosis is a chronic autoimmune disease of the central nervous system (CNS) that affects the brain, spinal cord, and optic nerves. It is an inflammatory demyelinating disorder and a leading cause of neurological disability in young adults.EpidemiologyMS commonly begins between 20 and 40 years of age and is twice as common in women. Its exact cause remains unclear, but genetic susceptibility contributes, with higher risk in first-degree relatives and identical twins. A greater...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Empiric azithromycin alters the upper respiratory microbiome and resistome without anti-inflammatory benefit in COVID-19.

Nature microbiology·2026

Same author

Author Correction: Machine learning models predict long COVID outcomes based on baseline clinical and immunologic factors.

Communications medicine·2026

Same author

Machine learning models predict long COVID outcomes based on baseline clinical and immunologic factors.

Communications medicine·2026

Same author

Host Genetic Architecture between Epstein-Barr Virus Activity and Multiple Sclerosis Reveals Shared Pathways.

medRxiv : the preprint server for health sciences·2025

Same author

Evaluating COVID-19 severity prediction and immune dynamics with NULISAseq: Insights from the IMPACC study.

Journal of immunology (Baltimore, Md. : 1950)·2025

Same author

Circulating endothelial signatures correlate with worse outcomes in COVID-19, respiratory failure and ARDS.

Critical care (London, England)·2025

Search research articles

Related Experiment Video

Updated: May 8, 2026

Two-photon Imaging of Cellular Dynamics in the Mouse Spinal Cord

Two-photon Imaging of Cellular Dynamics in the Mouse Spinal Cord

Published on: February 23, 2015

New therapeutic approaches for multiple sclerosis.

Philip L De Jager¹, David A Hafler

¹Center for Neurologic Diseases, Department of Neurology, Brigham & Women's Hospital, Boston, Massachusetts 02115, USA. pdejager@rics.bwh.harvard.edu

Annual Review of Medicine

|January 16, 2007

Summary

New research highlights the need for better treatments for multiple sclerosis (MS), focusing on both its inflammatory and neurodegenerative aspects. Tailoring immunotherapies to patient subsets offers a promising path forward for managing this central nervous system disease.

More Related Videos

A Protocol for the Use of Remotely-Supervised Transcranial Direct Current Stimulation (tDCS) in Multiple Sclerosis (MS)

A Protocol for the Use of Remotely-Supervised Transcranial Direct Current Stimulation (tDCS) in Multiple Sclerosis (MS)

Published on: December 26, 2015

Induction and Diverse Assessment Indicators of Experimental Autoimmune Encephalomyelitis

Induction and Diverse Assessment Indicators of Experimental Autoimmune Encephalomyelitis

Published on: September 9, 2022

Related Experiment Videos

Last Updated: May 8, 2026

Two-photon Imaging of Cellular Dynamics in the Mouse Spinal Cord

Two-photon Imaging of Cellular Dynamics in the Mouse Spinal Cord

Published on: February 23, 2015

A Protocol for the Use of Remotely-Supervised Transcranial Direct Current Stimulation (tDCS) in Multiple Sclerosis (MS)

A Protocol for the Use of Remotely-Supervised Transcranial Direct Current Stimulation (tDCS) in Multiple Sclerosis (MS)

Published on: December 26, 2015

Induction and Diverse Assessment Indicators of Experimental Autoimmune Encephalomyelitis

Induction and Diverse Assessment Indicators of Experimental Autoimmune Encephalomyelitis

Published on: September 9, 2022

Area of Science:

Neuroimmunology
Computational Biology
Genomics

Background:

Multiple sclerosis (MS) is a common inflammatory demyelinating disease of the central nervous system (CNS).
Current therapies primarily target inflammation, leaving the neurodegenerative component untreated.
Significant unmet needs exist for more effective immunomodulatory treatments and interventions for neurodegeneration in MS.

Purpose of the Study:

To explore advancements in understanding MS pathophysiology through integrated computational and high-throughput technologies.
To identify patient subsets with distinct demyelinating disease forms for personalized treatment strategies.
To address the dual challenges of shifting immune homeostasis and targeting neurodegeneration in MS.

Main Methods:

Leveraging 30 years of immunological research in MS.
Employing novel computational methods and high-throughput technologies (DNA, RNA, protein, metabolite analysis).
Characterizing variations in biological molecules to define patient subsets.

Main Results:

Progress in understanding MS immunology has been accelerated by new technologies.
Identification of distinct patient subsets with different forms of demyelinating disease is emerging.
Current approaches effectively manage inflammation but not neurodegeneration.

Conclusions:

Personalized immunotherapy, tailored to individual pathophysiologic processes, is a key future direction.
Developing combination therapies to restore immune homeostasis is crucial.
Identifying and modulating targets within the neurodegenerative component of MS is a critical challenge.